Compare GSK plc (GSK) vs JD.Com Inc (JD) Price & Performance

GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.

The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.

JD.com trades at $28.84, down 0.14% today, with strong analyst consensus of 32 buys and a $39.50 price target suggesting 37% upside. Recent quarters show consistent earnings beats, with Q1 2026 EPS of $0.74 exceeding expectations by 30%. Revenue grew to $1.31 trillion in 2025, though net margin compressed to 1.05%. Technical indicators signal bullish momentum with moving averages supporting upward trend while RSI levels indicate potential overbought conditions near current resistance.

JD presents compelling value with P/S of 0.22 and P/E of 21.5 below sector averages, supported by $234 billion cash position and aggressive buybacks. Risks include ongoing legal investigations, Chinese regulatory exposure, and margin pressure from intense e-commerce competition. The stock's valuation disconnect versus growth potential creates opportunity if execution improves.